Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-11-07
2008-12-30
Minnifield, N. M (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S002600, C424S184100, C424S278100, C424S275100, C536S023100, C530S387100
Reexamination Certificate
active
07470674
ABSTRACT:
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunostimulatory oligonucleotides according to the invention further comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.
REFERENCES:
patent: 5149798 (1992-09-01), Agrawal et al.
patent: 5366878 (1994-11-01), Pederson et al.
patent: 5635377 (1997-06-01), Pederson et al.
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5912332 (1999-06-01), Agrawal et al.
patent: 6143881 (2000-11-01), Metelev et al.
patent: 6346614 (2002-02-01), Metelev et al.
patent: 7045609 (2006-05-01), Metelev et al.
patent: 7105495 (2006-09-01), Agrawal et al.
patent: 7176296 (2007-02-01), Agrawal et al.
patent: 7262286 (2007-08-01), Kandimalla et al.
patent: 7276489 (2007-10-01), Agrawal et al.
patent: 7329648 (2008-02-01), Agrawal
patent: 7354907 (2008-04-01), Agrawal et al.
patent: 7405285 (2008-07-01), Agrawal et al.
patent: 7407944 (2008-08-01), Agrawal et al.
patent: 7427405 (2008-09-01), Agrawal et al.
patent: 2007/0105800 (2007-05-01), Agrawal et al.
patent: 2007/0105801 (2007-05-01), Agrawal et al.
patent: 2008/0152662 (2008-06-01), Agrawal et al.
patent: 2008/0193437 (2008-08-01), Agrawal et al.
patent: 2008/0206265 (2008-08-01), Kandimalla et al.
patent: 1393745 (2004-03-01), None
patent: WO 98/49288 (1998-11-01), None
patent: WO 01/12804 (2001-02-01), None
patent: US01/13682 (2001-04-01), None
patent: WO 01/55370 (2001-08-01), None
patent: US01/30137 (2001-09-01), None
patent: WO 2004/064782 (2004-08-01), None
patent: WO 2005/001055 (2005-01-01), None
patent: WO 2005/081847 (2005-09-01), None
patent: WO 2005/089231 (2005-09-01), None
patent: WO 2007/055682 (2007-05-01), None
patent: WO 2007/055704 (2007-05-01), None
Kandimalla et al, Current Opinion in Molecular Therapeutics, Apr. 2002, 4/2:122-129 (Abstract Only).
Yu et al, J. Med. Chem., 2002, 45:4540-4548.
Yu et al, Nucleic Acids Research, 2002, 30/20:4460-4469.
Zon, Gerald, “Oligonucleoside Phosphorothioates”, Protocols for Oligonucleotides and Analogs , 20:165-189 (1993).
Zon et al., “Phosphorothioate Oligonucleotides”, pp. 87-108 (1991).
Agrawal et al., “Modified Oligonucleotides as Therapeutic and Diagnostic Agents” Curr. Op. in Biotech., 6:12-19 (1995).
Antisense Research and Applications (Crooke and Lebleu, eds., CRC Press, Boca Raton (1993).
Khorana et al., “Studies on Polynucleotides”, J. Molec. Biol. 72:209-217 (1972).
Reese, Colin B., “The Chemical Synthesis of Oligo- and Poly-Nucleotides by the Phosphotriester Approach”, Tetrahedron Lett. 34:3143-3179 (1978).
Beaucage et al., “Deoxynucleoside Phosphoramidites-A New Class of Key Intermediates for Deoxypolynucleotide Synthesis”, Tetrahedron Lett. 22:1859-1862 (1981).
Agrawal et al., “Oligodeoxynucleoside Methylphosphonates: Synthesis and Enzymic Degradation”, Tetrahedron Lett. 28:3539-3542 (1987).
Connolly et al., “Synthesis and Characterization of an Octanucleotide Containing theEcoRI Recognition Sequence with a Phosphorotioate Group at the Cleavage Site”, Biochem. 23:3443-3453 (1984).
Jager et al., “Oligonucleotide N-Alkylphosphoramidates: Synthesis and Binding to Polynucleotides”, Biochem. 27:7237-7246 (1988).
Agrawal et al., “Oligodeoxynucleoside Phosphoramidates and Phosphorothiates as Inhibitors of Human Immunodeficiency Virus”, Proc. Natl. Acad. Sci. (USA) 85:7079-7083 (1988).
Kuramoto et al., “Oligonucleotides Sequences Required for natural Killer Cell Activation”, Jpn. J. Cancer Res. 83:1128-1131 (1992).
Krieg et al., “CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation”, Nature 371:546-549 (1995).
Liang et al., “Activation of Human B Cells by Phosphorothioate Oligodeoxynucleotides”, J. Clin. Invest. 92:1119-1129 (1996).
Moldoveanu et al., “CpG DNA A Novel Immune Enhancer . . . ” Vaccine 16:1216-1224 (1998).
McCluskie et al., “Cutting Edge: CpG DNA is a Potent . . . ” J. Immunol. 161:4463-4466 (1998).
Hartman et al., “Delineation of a CpG Phosphorothioate .. ” J. Immunol. 164:1617-1624 (2000).
Zhao et al., “Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation”, Biochem. Pharm. 51:173-182 (1996).
Zhao et al., “Modulation of Oligonucleotide-Induced Immune Stimulation by Cyclodextrin Analogs”, Biochem. Pharm. 52:1537-1544 (1996).
Zhao et al., “pattern and Kinetics of Cytokine production Following Administration of Phosphorotioate Oligonucleotides in Mice”, Antisense Nucleic Acid Drug Devel. 7:495-502 (1997).
Zhao et al., “Site of Chemical Modifications in CpG Containing Phosphotothioate Oligodeoxynucleotide Modulates Its Immunostimulatory Activity”, Bioorg. Med. Chem. Lett. 9:3453-3458 (1999).
Zhao et al., “Immunostimulatory Activity of CpG Containing . . . ”, Bioorg. Med. Chem. Lett. 10:1051-1054 (2000).
Yu et al., “Modulation of Immunostimulatory Activity of CpG Oligonucleotides by Site-specific Deletion of Nucleobases”, Bioorg. Med. Chem. Lett. 11:2263-2267 (2001).
Kandimalla et al., “Effect of Chemical Modifications of Cytosine and Guanine in a CpG Motif of Oligonucleotides: Structure-Immunostimulatory Activity Relationships”, Bioorg. Med. Chem. 9:807-813 (2001).
Remington's Pharmaceutical Sciences, 18thEdition, ed., A. Gennaro, Mack Publishing Co., Easton, PA, 1990.
Agrawal Sudhir
Kandimalla Ekambar
Yu Dong
Idera Pharmaceuticals Inc.
Keown Wayne A.
Keown & Zucchero, LLP
Minnifield N. M
Zucchero Joseph C.
LandOfFree
Immunostimulatory properties of oligonucleotide-based... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunostimulatory properties of oligonucleotide-based..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunostimulatory properties of oligonucleotide-based... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4034239